Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Ion transport in muscle acetylcholine receptor maintained by conserved salt bridges between the pore and lipid membrane
Alhalhooly, Lina , Sine, Steven M.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 8, 2024 | Volume: 121 | Issue: 16 | Pages: No page available

10.1073/pnas.2320416121 | PMID 38588428 Get It

Pores through ion channels rapidly transport small inorganic ions along their electrochemical gradients. Here, applying single-channel electrophysiology and mutagenesis to the archetypal muscle nicotinic acetylcholine receptor (AChR) channel, we show that a conserved pore-peripheral salt bridge partners with those in the other subunits to regulate ion transport. Disrupting the salt bridges in all five receptor subunits greatly decreases the amplitude of the unitary current and increases its fluctuations. However, disrupting individual salt bridges has unequal effects that depend on the structural status of the other salt bridges. The AChR ε- and δ-subunits are structurally unique in harboring a putative palmitoylation site near each salt bridge and bordering the lipid membrane. The effects of disrupting the palmitoylation sites mirror those of disrupting the salt bridges, but the effect of disrupting either of these structures depends on the structural status of the other. Thus, rapid ion transport through the AChR channel is maintained by functionally interdependent salt bridges linking the pore to the lipid membrane.
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
Gallois, Claire , Shi, Qian , Pederson, Levi , André, Thierry , Sobrero, Alberto F. , Alberts, Steven R. , Gramont, Aimery de , Meyerhardt, Jeffrey A. , George, Thomas J. , Souglakos, Ioannis , Harkin, Andrea , Shields, Anthony F. , Boukovinas, Ioannis , Goldberg, Richard M. , Papamichael, Demetris , Pederson, Levi D , Iveson, Timothy J , Sobrero, Alberto , Alberts, Steven R , De Gramont, Aimery , Meyerhardt, Jeffrey A , George, Thomas J , Schmoll, Hans-Joachim , Harkin, Andrea , Sinicrope, Frank A , Oki, Eiji , Shields, Anthony F , Boukovinas, Ioannis , Lonardi, Sara , Yothers, Greg , Yoshino, Takayuki , Goldberg, Richard M , Taieb, Julien , Papamichael, Demetris , André, Thierry , Shi, Qian , Iveson, Timothy , Schmoll, Hans‐Joachim , Labianca, Roberto , Sinicrope, Frank A. , Oki, Eiji , Kerr, Rachel , Lonardi, Sara , Yothers, Greg , Yoshino, Takayuki , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | March 28, 2024 | Volume: 42 | Issue: 19 | Pages: 2295-2305

10.1200/jco.23.01326 | PMID 38547438 Get It

PURPOSE A number of studies suggest that older patients may have reduced or no benefit from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon cancer (CC). MATERIALS AND METHODS We studied the prognostic impact of age, as well as treatment adherence/toxicity patterns according to age, in patients with stage III CC who received 3 or 6 months of infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (CAPOX) on the basis of data collected from trials from the ACCENT and IDEA databases. Associations between age and time to recurrence (TTR), disease-free survival (DFS), overall survival (OS), survival after recurrence (SAR), and cancer-specific survival (CSS) were assessed by a Cox model or a competing risk model, stratified by studies and adjusted for sex, performance status, T and N stage, and year of enrollment. RESULTS A total of 17,909 patients were included; 24% of patients were age older than 70 years (n = 4,340). Patients age ≥70 years had higher rates of early treatment discontinuation. Rates of grade ≥3 adverse events were similar between those older and younger than 70 years, except for diarrhea and neutropenia that were more frequent in older patients treated with CAPOX (14.2% v 11.2%; P = .01 and 12.1% v 9.6%; P = .04, respectively). In multivariable analysis, TTR was not significantly different between patients <70 years and those ≥70 years, but DFS, OS, SAR, and CSS were significantly shorter in those patients ≥70 years. CONCLUSION In patients ≥70 years with stage III CC fit enough to be enrolled in clinical trials, oxaliplatin-based adjuvant chemotherapy was well tolerated and led to similar TTR compared with younger patients, suggesting similar efficacy. TTR may be a more appropriate end point for efficacy in this patient population.
Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future
Abbas, Mohammed Tiseer , Ali, Nima Baba , Farina, Juan M. , Mahmoud, Ahmed , Pereyra, Milagros , Scalia, Isabel G. , Kamel, Moaz, Barry, Timothy , Lester, Steven J., Cannan, Charles R., Mital, Rohit , Wilansky, Susan , Freeman, William K., Alsidawi, Said , Arsanjani, Reza , Baba Ali, Nima, Kamel, Moaz A, Alsidawi, Said , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Mahmoud, Ahmed K , Scalia, Isabel G , Abbas, Mohammed Tiseer , Chao, Chieh‐Ju

Mayo Clinic

Biomedicines | March 19, 2024 | Volume: 12 | Issue: 3 | Pages: 682

10.3390/biomedicines12030682 | PMID 38540296 Get It

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. It follows an autosomal dominant inheritance pattern in most cases, with incomplete penetrance and heterogeneity. It is familial in 60% of cases and most of these are caused by pathogenic variants in the core sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1). Genetic testing using targeted disease-specific panels that utilize next-generation sequencing (NGS) and include sarcomeric genes with the strongest evidence of association and syndrome-associated genes is highly recommended for every HCM patient to confirm the diagnosis, identify the molecular etiology, and guide screening and management. The yield of genetic testing for a disease-causing variant is 30% in sporadic cases and up to 60% in familial cases and in younger patients with typical asymmetrical septal hypertrophy. Genetic testing remains challenging in the interpretation of results and classification of variants. Therefore, in 2015 the American College of Medical Genetics and Genomics (ACMG) established guidelines to classify and interpret the variants with an emphasis on the necessity of periodic reassessment of variant classification as genetic knowledge rapidly expands. The current guidelines recommend focused cascade genetic testing regardless of age in phenotype-negative first-degree relatives if a variant with decisive evidence of pathogenicity has been identified in the proband. Genetic test results in family members guide longitudinal clinical surveillance. At present, there is emerging evidence for genetic test application in risk stratification and management but its implementation into clinical practice needs further study. Promising fields such as gene therapy and implementation of artificial intelligence in the diagnosis of HCM are emerging and paving the way for more effective screening and management, but many challenges and obstacles need to be overcome before establishing the practical implications of these new methods.
Radiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial
Rades, Dirk , Lomidze, Darejan, Jankarashvili, Natalia , López‐Campos, Fernando , Navarro-Martín, Arturo , Šegedin, Barbara , Grošelj, Blaž , Staackmann, Christian, Kristiansen, Charlotte , Dennis, Kristopher , Schild, Steven E. , Cacicedo, Jon , Kristiansen, Charlotte , Schild, Steven

Mayo Clinic

Cancers | March 14, 2024 | Volume: 16 | Issue: 6 | Pages: 1149

10.3390/cancers16061149 | PMID 38539484 Get It

Patients with metastatic epidural spinal cord compression (MESCC) and favorable survival prognoses may benefit from radiation doses exceeding 10 × 3.0 Gy. In a multi-center phase 2 trial, patients receiving 15 × 2.633 Gy (41.6 Gy10) or 18 × 2.333 Gy (43.2 Gy10) were evaluated for local progression-free survival (LPFS), motor/sensory functions, ambulatory status, pain, distress, toxicity, and overall survival (OS). They were compared (propensity score-adjusted Cox regression) to a historical control group (n = 266) receiving 10 × 3.0 Gy (32.5 Gy10). In the phase 2 cohort, 50 (of 62 planned) patients were evaluated for LPFS. Twelve-month rates of LPFS and OS were 96.8% and 69.9%, respectively. Motor and sensory functions improved in 56% and 57.1% of patients, and 94.0% were ambulatory following radiotherapy. Pain and distress decreased in 84.4% and 78.0% of patients. Ten and two patients experienced grade 2 and 3 toxicities, respectively. Phase 2 patients showed significantly better LPFS than the control group (p = 0.039) and a trend for improved motor function (p = 0.057). Ambulatory and OS rates were not significantly different. Radiotherapy with 15 × 2.633 Gy or 18 × 2.333 Gy was well tolerated and appeared superior to 10 × 3.0 Gy.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Fleischmann, Roy , Mysler, Eduardo , Greenwald, Maria , Ytterberg, Steven R. , Koch, Gary G., Bhatt, Deepak L. , Wang, Cunshan, Mikuls, Ted R. , Chen, All‐shine, Connell, Carol A., Woolcott, John , Menon, Sujatha, Chen, Yan , Lee, Kristen , Fleischmann, Roy , Mikuls, Ted R , Szekanecz, Zoltán , Bhatt, Deepak L , Charles‐Schoeman, Christina

Mayo Clinic

Arthritis & Rheumatology | March 14, 2024 | Volume: 76 | Issue: 8 | Pages: 1218-1229

10.1002/art.42846 | PMID 38481002 Get It

Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. Methods Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient‐years) by 6‐month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. Results Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6‐month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m 2 , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. Conclusion Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
Proximal Humerus Reconstruction for Bone Sarcomas
Houdek, Matthew T. , Sullivan, Mikaela H. , Broida, Samuel E. , Barlow, Jonathan D. , Moran, Steven L. , Sánchez‐Sotelo, Joaquín , Moran, Steven L , Sanchez-Sotelo, J. , Houdek, Matthew T , Barlow, Jonathan D , Broida, Samuel E , Morrey, Mark E.

Mayo Clinic

JBJS Reviews | March 11, 2024 | Volume: 12 | Issue: 3 | Pages: No page available

10.2106/jbjs.rvw.23.00217 | PMID 38466801 Get It

» The proximal humerus is a common location for primary bone tumors, and the goal of surgical care is to obtain a negative margin resection and subsequent reconstruction of the proximal humerus to allow for shoulder function. » The current evidence supports the use of reverse total shoulder arthroplasty over hemiarthroplasty when reconstructing the proximal humerus after resection of a bone sarcoma if the axillary nerve can be preserved. » There is a lack of high-quality data comparing allograft prosthetic composite (APC) with endoprosthetic reconstruction of the proximal humerus. » Reverse APC should be performed using an allograft with donor rotator cuff to allow for soft-tissue repair of the donor and host rotator cuff, leading to improvements in shoulder motion compared with an endoprosthesis.
Structural bases for stoichiometry‐selective calcium potentiation of a neuronal nicotinic receptor
Mazzaferro, Simone , Kang, Guipeun , Natarajan, Kathiresan , Hibbs, Ryan , Sine, Steven M. , Hibbs, Ryan E

Mayo Clinic

British Journal of Pharmacology | March 8, 2024 | Volume: 181 | Issue: 13 | Pages: 1973-1992

10.1111/bph.16321 | PMID 38454578 Get It

Background and Purpose α4β2 nicotinic acetylcholine (nACh) receptors assemble in two stoichiometric forms, one of which is potentiated by calcium. The sites of calcium binding that underpin potentiation are not known. Experimental Approach To identify calcium binding sites, we applied cryo‐electron microscopy (cryo‐EM) and molecular dynamics (MD) simulations to each stoichiometric form of the α4β2 nACh receptor in the presence of calcium ions. To test whether the identified calcium sites are linked to potentiation, we generated mutants of anionic residues at the sites, expressed wild type and mutant receptors in clonal mammalian fibroblasts, and recorded ACh‐elicited single‐channel currents with or without calcium. Key Results Both cryo‐EM and MD simulations show calcium bound to a site between the extracellular and transmembrane domains of each α4 subunit (ECD‐TMD site). Substituting alanine for anionic residues at the ECD‐TMD site abolishes stoichiometry‐selective calcium potentiation, as monitored by single‐channel patch clamp electrophysiology. Additionally, MD simulation reveals calcium association at subunit interfaces within the extracellular domain. Substituting alanine for anionic residues at the ECD sites reduces or abolishes stoichiometry‐selective calcium potentiation. Conclusions and Implications Stoichiometry‐selective calcium potentiation of the α4β2 nACh receptor is achieved by calcium association with topographically distinct sites framed by anionic residues within the α4 subunit and between the α4 and β2 subunits. Stoichiometry‐selective calcium potentiation could result from the greater number of calcium sites in the stoichiometric form with three rather than two α4 subunits. The results are relevant to modulation of signalling via α4β2 nACh receptors in physiological and pathophysiological conditions.
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
Schuetze, Scott M. , Heise, Rachel S. , Ganjoo, Kristen N. , Davis, Elizabeth J. , George, Suzanne , Burgess, Melissa , Choy, Edwin , Shepard, Dale R. , Tinoco, Gabriel , Kelly, Ciara M. , Attia, Steven , Deshpande, Hari A. , Riedel, Richard F. , Kozlowski, Erin , Astbury, Caroline , Ballman, Karla V. , Schuetze, Scott M , Heise, Rachel , Ganjoo, Kristen N , Davis, Elizabeth J , George, Suzanne , Burgess, Melissa A , Choy, Edwin , Shepard, Dale R , Tinoco, Gabriel , Hirbe, Angela C , Kelly, Ciara M , Attia, Steven , Deshpande, Hari A , Schwartz, Gary K , Siontis, Brittany L , Riedel, Richard F , von Mehren, Margaret , Kozlowski, Erin , Chen, Helen X , Astbury, Caroline , Rubin, Brian P. , Ballman, Karla , Hirbe, Angela C. , Schwartz, Gary K. , Siontis, Brittany L. , Mehren, Margaret von

Mayo Clinic

Clinical Cancer Research | March 6, 2024 | Volume: 30 | Issue: 20 | Pages: 4584-4592

10.1158/1078-0432.ccr-23-3817 | PMID 38446990 Get It

Abstract Purpose: Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ–CAMTA1 (calmodulinbinding transcription activator 1) operating as an oncogenic driver through activation of the MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE. Patients and Methods: A phase 2 trial of trametinib was conducted in patients with locally advanced or metastatic EHE. Eligibility requirements included evidence of tumor progression or presence of EHE-related pain requiring opiates for management before enrollment. The primary endpoint was objective response rate (ORR) as per RECIST1.1 in cases with TAZ– CAMTA1 confirmed by fusion-FISH. Secondary objectives were to estimate ORR for all patients, median progression-free survival (PFS), 2-year overall survival (OS) rate, patient safety, and change in patient-reported global health and pain scores per PROMIS questionnaires. Results: 44 patients enrolled and 42 started trametinib. TAZ– CAMTA1 was detected in 27 tumor samples. TheORRwas 3.7%[95% confidence interval (CI), 0.094–19.0], median PFS was 10.4 months (95%CI, 7.1–NA), and 2-year OS rate was 33.3%(95%CI, 19.1–58.2) in the target population. Median pain intensity and interference scores improved significantly after 4 weeks of trametinib in patients using opiates. Common adverse events related to trametinib were rash, fatigue, nausea/vomiting, diarrhea/constipation, alopecia, and edema; one grade 5 ARDS/pneumonitis was related to trametinib. Conclusions: Trametinib was associated with reduction in EHE-related pain and median PFS of more than 6 months, providing palliative benefit in patients with advanced EHE, but the trial did not meet the ORR goal. See related commentary by Van Tine and Haarberg, p. 4552
A CASPASE 8‐CATHEPSIN B PROTEASE CASCADE CONTRIBUTES TO BILE SALT‐INDUCED HEPATOCYTE APOPTOSIS
Faubion, William A. , Roberts, Patricia J., Bronk, Steven F., Agellon, L. B., Gores, G. J.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 22, 2024 | Volume: 26 | Issue: 5 | Pages: 573-573

10.1002/j.1536-4801.1998.tb01009.x Get It

Comparative Analysis of Two Hemiarthroplasty Techniques for Symptomatic Distal Radial Ulnar Joint Arthritis
Hebel, Nathan , Wu, Kitty Y. , Helsper, Elizabeth, Hassan, Bassem El, Rizzo, Marco , Moran, Steven L. , El Hassan, Bassem, Kakar, Sanjeev

Mayo Clinic

Journal of Wrist Surgery | January 31, 2024 | Volume: 14 | Issue: 02 | Pages: 144-150

10.1055/s-0044-1779498 | PMID 40151782 Get It

Abstract Background Hemiarthroplasty may be indicated for patients with distal radioulnar joint (DRUJ) arthritis. Recently, the use of the pyrocarbon metacarpophalangeal implant has been proposed as a novel means of treating DRUJ arthritis due to the materials improved mechanical properties and wear characteristics. Purpose This study compares midterm outcomes of metallic and pyrocarbon hemiarthroplasties for the treatment of symptomatic DRUJ arthritis. Questions of interest included outcomes and complications. Materials and Methods In total, 32 hemiarthroplasties, 10 metallic and 22 pyrocarbon, were performed between 2010 and 2020 by three surgeons at one tertiary medical center. Patients' retrospective outcomes were extracted from the electronic medical record. Results Postoperatively, the metallic implant group (mean follow-up: 38 months) demonstrated decreased pain but no changes in range of motion. Comparatively, the pyrocarbon group experienced an improved range of motion and postoperative pain (p < 0.05). Radiographic analysis demonstrated 10% of metallic implants and 9% of pyrocarbon implants to have resulted in thinning of the lateral cortex of the radius at the final follow-up. Minor complications in metallic and pyrocarbon implant groups warranting reoperation occurred at rates of 10 and 13.5% while implant failure occurred at a rate of 30 and 18%, respectively. Discussion Within this study, pyrocarbon implants resulted in significant functional improvement with comparable complication and failure rates to the metallic implant. Long-term stability demonstrated efficacy for both techniques in symptomatic DRUJ treatment. Type of Study/Level of Evidence Observational Case Series IV.